Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia-Reference-Cited by-同舟云学术

Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia

Published:2012-10-10 Issue:2 Volume:92 Page:179-183
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Tiribelli Mario,Latagliata Roberto,Luciano Luigiana,Castagnetti Fausto,Gozzini Antonella,Cambrin Giovanna Rege,Annunziata Mario,Stagno Fabio,Pregno Patrizia,Albano Francesco,Abruzzese Elisabetta,Musto Pellegrino,Montefusco Enrico,Fava Carmen,Fanin Renato,Pane Fabrizio,Rosti Gianantonio,Breccia Massimo,Alimena Giuliana,Vigneri Paolo

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00277-012-1591-2.pdf

Reference17 articles.

1. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876–880

2. von Bubnoff N, Schneller F, Peschel C, Duyster J (2002) BCRABL gene mutations in relation to clinical resistance of Philadelphia chromosome-positive leukaemia to STI571: a prospective study. Lancet 359:487–491

3. Soverini S, Martinelli G, Rosti G, Bassi S, Amabile M, Poerio A, Giannini B, Trabacchi E, Castagnetti F, Testoni N, Luatti S, de Vivo A, Cilloni D, Izzo B, Fava M, Abruzzese E, Alberti D, Pane F, Saglio G, Baccarani M (2005) ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol 23:4100–4109

4. Jabbour E, Kantarjian H, Jones D, Talpaz M, Bekele N, O’Brien S, Zhou X, Luthra R, Garcia-Manero G, Giles F, Rios MB, Verstovsek S, Cortes J (2006) Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 20:1767–1773

5. Soverini S, Colarossi S, Gnani A, Rosti G, Castagnetti F, Poerio A, Iacobucci I, Amabile M, Abruzzese E, Orlandi E, Radaelli F, Ciccone F, Tiribelli M, di Lorenzo R, Caracciolo C, Izzo B, Mane F, Saglio G, Baccarani M, Martinelli G, GIMEMA Working Party on Chronic Myeloid Leukemia (2006) Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukaemia. Clin Cancer Res 12:7374–7379

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Flavonoids as omnipotent candidates for cancer management;South African Journal of Botany;2023-07

2. Nanocracker capable of simultaneously reversing both P-glycoprotein and tumor microenvironment;Journal of Controlled Release;2023-02

3. Ferroptosis‐modulating small molecules for targeting drug‐resistant cancer: Challenges and opportunities in manipulating redox signaling;Medicinal Research Reviews;2023-01-19

4. Scopoletin: Anticancer potential and mechanism of action;Asian Pacific Journal of Tropical Biomedicine;2023

5. Itraconazole synergistically increases therapeutic effect of paclitaxel and 99mTc-MIBI accumulation, as a probe of P-gp activity, in HT-29 tumor-bearing nude mice;European Journal of Pharmacology;2021-03